在使用免疫疗法进行的3期生殖尿路癌症试验中,非免疫疗法手臂配置
Abby L Grier1, Albert Jang2, Jeffrey Y Zhong1
1School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH.
Clinical genitourinary cancer
|January 13, 2026
概括
在临床试验中进展后,许多患有晚期生殖尿道癌症的患者没有接受免疫检查点抑制剂. 需要进一步的研究来理解这种不一致的后续癌症治疗方法的使用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 免疫检查点抑制剂 (ICI) 是晚期生殖尿道癌症的标准治疗方法.
- 了解后续治疗的使用对于优化患者的治疗结果至关重要.
研究的目的:
- 评估ICI作为癌症免疫疗法III期试验中的患者的后续治疗的利用.
- 在疾病进展后评估ICI在对照组中的使用一致性.
主要方法:
- 对11项注册的III期免疫疗法试验的分析,总体生存益处.
- 在对照组患有细胞癌和尿路细胞癌的患者中评估后续治疗模式.
主要成果:
- 在细胞癌 (n=5135) 中,约60%的对照患者接受了随后的治疗,其中70%接受了ICI.
- 在尿路癌 (n=3445) 中,54%的对照患者接受了随后的治疗,其中69%的患者接受了ICI.
结论:
- 在这些试验中,对照组的患者在进展后并不始终接受ICI.
- 需要进一步的研究,以了解后续治疗接入对整体存活率的影响,并确定影响不一致提供的因素.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.1K
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K